BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE: TGX), a medical device company serving the prostate cancer treatment and surgical products markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2007. Consolidated revenue for the quarter was $15.2 million compared to $14.8 million in the fourth quarter of 2006, an increase of 3%. For the year, consolidated revenue was $62.2 million, the highest annual revenue in the Company’s history, compared to $54.1 million in 2006, an increase of 15%. Net income for the quarter was $1.2 million, or $0.03 per diluted share, compared to net income of $4.0 million, or $0.12 per diluted share in the fourth quarter of 2006. For the year, net income was $5.6 million, or $0.17 per diluted share, compared to net income of $6.9 million, or $0.21 per diluted share in 2006. Results for the 2006 periods include the results of Galt Medical from August 2, 2006, the date Galt was acquired by Theragenics.
